Evidence map›Paper›PMID 42845921›Full record

ArticleFrontiers in medicine2026

Case Report: Fulminant meningococcus-meningitis under treatment with ravulizumab despite complete vaccination-a rare but severe complication.

Gábor Kozák, Stefan Förster, Michael Haap, Reimer Riessen, Samuel Böhm-Gonzalez, Jan-Hendrik Stahl, Alexander Grimm, Ulf Ziemann, Siri Göpel, Josua Kegele and 2 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gábor KozákDepartment for Vascular Neurology, Centre for Neurology, University of Tübingen, Tübingen, Germany.
Stefan FörsterDepartment for Vascular Neurology, Centre for Neurology, University of Tübingen, Tübingen, Germany.
Michael HaapDepartment of Medicine, Medical Intensive Care Unit, University Hospital Tübingen, Tübingen, Germany.
Reimer RiessenDepartment of Medicine, Medical Intensive Care Unit, University Hospital Tübingen, Tübingen, Germany.
Samuel Böhm-GonzalezDepartment for Epileptology, Centre for Neurology, University of Tübingen, Tübingen, Germany.
Jan-Hendrik StahlDepartment for Epileptology, Centre for Neurology, University of Tübingen, Tübingen, Germany.
Alexander GrimmDepartment for Epileptology, Centre for Neurology, University of Tübingen, Tübingen, Germany.
Ulf ZiemannDepartment for Vascular Neurology, Centre for Neurology, University of Tübingen, Tübingen, Germany.
Siri GöpelDivision of Infectious Diseases, Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany.
Josua KegeleDepartment for Epileptology, Centre for Neurology, University of Tübingen, Tübingen, Germany.
Annerose Mengel *Department for Vascular Neurology, Centre for Neurology, University of Tübingen, Tübingen, Germany.
Katharina Feil *Department for Vascular Neurology, Centre for Neurology, University of Tübingen, Tübingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Complement C5 inhibitors such as ravulizumab are increasingly used for acetylcholine receptor-positive generalized myasthenia gravis (MG) but confer a relevant risk of invasive meningococcal infection. We report a rare case of fulminant meningococcal meningitis despite complete vaccination, highlighting the limits of current preventive strategies. Methods: Case report. Results: A 41-year-old woman with acetylcholine receptor-positive MG was treated with ravulizumab after two-dose series meningococcal vaccination (MenACWY and MenB). One month after therapy initiation, she presented with nausea, vomiting and rapidly developed impaired consciousness. CSF showed neutrophilic pleocytosis, hypoglycorrhachia, and high lactate, consistent with bacterial meningitis. Rapid testing and culture confirmed Discussion: This case illustrates that vaccination does not abolish the risk of fulminant meningococcal infection under complement inhibition. Awareness, patient information, and rapid initiation of antibiotics are critical. Clinicians should counsel patients and relatives that meningitis may occur despite vaccination and promote early recognition strategies.

Indexed as

complement therapiesmeningitismeningitis vaccinesmyasthenia gravisravulizumab

Identifiers

PMID42845921
PMCPMC13642633

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.